CORT
Price
$83.87
Change
+$1.14 (+1.38%)
Updated
Sep 26 closing price
Capitalization
8.84B
31 days until earnings call
DNLI
Price
$13.95
Change
+$0.52 (+3.87%)
Updated
Sep 26 closing price
Capitalization
2.04B
32 days until earnings call
Interact to see
Advertisement

CORT vs DNLI

Header iconCORT vs DNLI Comparison
Open Charts CORT vs DNLIBanner chart's image
Corcept Therapeutics
Price$83.87
Change+$1.14 (+1.38%)
Volume$482.98K
Capitalization8.84B
Denali Therapeutics
Price$13.95
Change+$0.52 (+3.87%)
Volume$2.33M
Capitalization2.04B
CORT vs DNLI Comparison Chart in %
Loading...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CORT vs. DNLI commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CORT is a Buy and DNLI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (CORT: $83.87 vs. DNLI: $13.95)
Brand notoriety: CORT and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CORT: 57% vs. DNLI: 114%
Market capitalization -- CORT: $8.84B vs. DNLI: $2.04B
CORT [@Biotechnology] is valued at $8.84B. DNLI’s [@Biotechnology] market capitalization is $2.04B. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CORT’s FA Score shows that 1 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CORT’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, CORT is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CORT’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • CORT’s TA Score: 5 bullish, 5 bearish.
  • DNLI’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CORT is a better buy in the short-term than DNLI.

Price Growth

CORT (@Biotechnology) experienced а +4.16% price change this week, while DNLI (@Biotechnology) price change was +9.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

CORT is expected to report earnings on Oct 29, 2025.

DNLI is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CORT($8.84B) has a higher market cap than DNLI($2.04B). CORT YTD gains are higher at: 66.442 vs. DNLI (-31.551). CORT has higher annual earnings (EBITDA): 104M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. CORT (342M). CORT has less debt than DNLI: CORT (6.61M) vs DNLI (46.6M). CORT has higher revenues than DNLI: CORT (716M) vs DNLI (0).
CORTDNLICORT / DNLI
Capitalization8.84B2.04B433%
EBITDA104M-521.52M-20%
Gain YTD66.442-31.551-211%
P/E Ratio74.88N/A-
Revenue716M0-
Total Cash342M899M38%
Total Debt6.61M46.6M14%
FUNDAMENTALS RATINGS
CORT vs DNLI: Fundamental Ratings
CORT
DNLI
OUTLOOK RATING
1..100
3918
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
34100
SMR RATING
1..100
4397
PRICE GROWTH RATING
1..100
3984
P/E GROWTH RATING
1..100
1099
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CORT's Valuation (83) in the Pharmaceuticals Other industry is in the same range as DNLI (93) in the Biotechnology industry. This means that CORT’s stock grew similarly to DNLI’s over the last 12 months.

CORT's Profit vs Risk Rating (34) in the Pharmaceuticals Other industry is significantly better than the same rating for DNLI (100) in the Biotechnology industry. This means that CORT’s stock grew significantly faster than DNLI’s over the last 12 months.

CORT's SMR Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (97) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than DNLI’s over the last 12 months.

CORT's Price Growth Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (84) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than DNLI’s over the last 12 months.

CORT's P/E Growth Rating (10) in the Pharmaceuticals Other industry is significantly better than the same rating for DNLI (99) in the Biotechnology industry. This means that CORT’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CORTDNLI
RSI
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
70%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 21 days ago
77%
Declines
ODDS (%)
Bearish Trend 14 days ago
66%
Bearish Trend 14 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
70%
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bearish Trend 3 days ago
41%
Bullish Trend 3 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GMOUX32.280.35
+1.10%
GMO International Equity I
PFPFX56.840.62
+1.10%
Poplar Forest Partners A
ATGRX14.060.10
+0.72%
American Century International Gr R
HDGVX37.770.24
+0.65%
Hartford Dividend and Growth R6
JGQYX18.260.06
+0.33%
Jensen Global Quality Growth Y

CORT and

Correlation & Price change

A.I.dvisor indicates that over the last year, CORT has been loosely correlated with VTVT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CORT jumps, then VTVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CORT
1D Price
Change %
CORT100%
+1.38%
VTVT - CORT
49%
Loosely correlated
-2.10%
DNLI - CORT
40%
Loosely correlated
+3.87%
TENX - CORT
38%
Loosely correlated
+6.61%
ARCT - CORT
38%
Loosely correlated
+9.16%
HNSBF - CORT
38%
Loosely correlated
N/A
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+3.87%
NRIX - DNLI
59%
Loosely correlated
+7.20%
OCUL - DNLI
54%
Loosely correlated
+2.37%
RGNX - DNLI
54%
Loosely correlated
+3.10%
BEAM - DNLI
54%
Loosely correlated
-0.52%
IMVT - DNLI
54%
Loosely correlated
+3.57%
More